References
- 1. VITALI C., BOMBARDIERI S., JONSSON R., MOUTSOPOULOS HM., ALEXANDER EL., CARSONS SE., et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
- 2. ALANI H., HENTY JR., THOMPSON NL., JURY E., CIURTIN C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018;47(2):141–54.
- 3. BROWN LE., FRITS ML., IANNACCONE CK., WEINBLATT ME., SHADICK NA., LIAO KP. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford). 2015;54(5):816–20.
- 4. KIM SM., PARK E., LEE JH., LEE SH., KIM HR. The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int. 2012;32(12):3963–7.
- 5. LEE J., KOH JH., KIM JW., SUNG YK., LEE SS., CHOE JY., et al. Performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome in a Korean cohort. Rheumatol Int. 2018;38(9):1651–60.
- 6. TEN BRINCK RM., VAN STEENBERGEN HW., VAN DELFT MAM., VERHEUL MK., TOES REM., TROUW LA., et al. The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. Rheumatology (Oxford). 2017;56(12):2145–53.
- 7. NISHIMURA K., SUGIYAMA D., KOGATA Y., TSUJI G., NAKAZAWA T., KAWANO S., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808.
- 8. PERRY E., KELLY C., EGGLETON P., DE SOYZA A., HUTCHINSON D. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford). 2014;53(11):1940–50.
- 9. LAPPIN DF., APATZIDOU D., QUIRKE AM., OLIVER-BELL J., BUTCHER JP., KINANE DF., et al. Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres. J Clin Periodontol. 2013;40(10):907–15.
- 10. MARESZ KJ., HELLVARD A., SROKA A., ADAMOWICZ K., BIELECKA E., KOZIEL J., et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 2013;9(9):e1003627.
- 11. HUTCHINSON D., SHEPSTONE L., MOOTS R., LEAR JT., LYNCH MP. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis. 2001;60(3):223–7.
- 12. KALLBERG H., DING B., PADYUKOV L., BENGTSSON C., RONNELID J., KLARESKOG L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70(3):508–11.
- 13. MAKRYGIANNAKIS D., HERMANSSON M., ULFGREN AK., NICHOLAS AP., ZENDMAN AJ., EKLUND A., et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–92.
- 14. KLARESKOG L., STOLT P., LUNDBERG K., KALLBERG H., BENGTSSON C., GRUNEWALD J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.
- 15. KLARESKOG L., RONNELID J., LUNDBERG K., PADYUKOV L., ALFREDSSON L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651–75.
- 16. RUIZ-ESQUIDE V., GOMARA MJ., PEINADO VI., GOMEZ PUERTA JA., BARBERA JA., CANETE JDE D., et al. Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? Clin Rheumatol. 2012;31(7):1047–50.
- 17. PABST R., GEHRKE I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am J Respir Cell Mol Biol. 1990;3(2):131–5.
- 18. PABST R. Is BALT a major component of the human lung immune system? Immunol Today. 1992;13(4):119–22.
- 19. RANGEL-MORENO J., HARTSON L., NAVARRO C., GAXIOLA M., SELMAN M., RANDALL TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183–94.
- 20. BAKA Z., GYORGY B., GEHER P., BUZAS EI., FALUS A., NAGY G. Citrullination under physiological and pathological conditions. Joint Bone Spine. 2012;79(5):431–6.
- 21. KAWAHITO Y., ICHINOSE S., SANO H., TSUBOUCHI Y., KOHNO M., YOSHIKAWA T., et al. Mycoplasma fermentans glycolipid-antigen as a pathogen of rheumatoid arthritis. Biochem Biophys Res Commun. 2008;369(2):561–6.